{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T15:51:22Z","timestamp":1791993082903,"version":"4.4.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32172844"],"award-info":[{"award-number":["32172844"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002767","name":"Hunan Provincial Science and Technology Department","doi-asserted-by":"publisher","award":["2021NK1030"],"award-info":[{"award-number":["2021NK1030"]}],"id":[{"id":"10.13039\/501100002767","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.ijbiomac.2023.123979","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T02:19:09Z","timestamp":1678414749000},"page":"123979","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines"],"prefix":"10.1016","volume":"236","author":[{"given":"Dongliang","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youqing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal D.","family":"Epstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ijbiomac.2023.123979_bb0005","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/nri2868","article-title":"Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns","volume":"10","author":"Bachmann","year":"2010","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.123979_bb0010","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1681","article-title":"Advancements in protein nanoparticle vaccine platforms to combat infectious disease","volume":"13","author":"Butkovich","year":"2021","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s12951-021-00806-7","article-title":"Virus-like particles: preparation, immunogenicity and their roles as nanovaccines and drug nanocarriers","volume":"19","author":"Nooraei","year":"2021","journal-title":"J. Nanobiotechnol."},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.123979_bb0020","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0966-842X(03)00208-7","article-title":"Virus-like particles as immunogens","volume":"11","author":"Noad","year":"2003","journal-title":"Trends Microbiol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.123979_bb0025","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1080\/14760584.2020.1738227","article-title":"Genetic engineering strategies for construction of multivalent chimeric VLPs vaccines","volume":"19","author":"Lei","year":"2020","journal-title":"Expert Rev. Vacc."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.123979_bb0030","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1007\/s12274-021-3832-y","article-title":"Review: development of SARS-CoV-2 immuno-enhanced COVID-19 vaccines with nano-platform","volume":"15","author":"Sa-Nguanmoo","year":"2022","journal-title":"Nano Res."},{"issue":"24","key":"10.1016\/j.ijbiomac.2023.123979_bb0035","doi-asserted-by":"crossref","first-page":"13445","DOI":"10.3390\/ijms222413445","article-title":"Protein-based nanoparticle vaccines for SARS-CoV-2","volume":"22","author":"Sung","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0040","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ymeth.2006.07.018","article-title":"Virus-like particles: passport to immune recognition","volume":"40","author":"Grgacic","year":"2006","journal-title":"Methods"},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.123979_bb0045","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/eji.200737984","article-title":"Nanoparticles target distinct dendritic cell populations according to their size","volume":"38","author":"Manolova","year":"2008","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0050","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41541-021-00330-7","article-title":"Protein-based antigen presentation platforms for nanoparticle vaccines","volume":"6","author":"Nguyen","year":"2021","journal-title":"NPJ Vacc."},{"key":"10.1016\/j.ijbiomac.2023.123979_bb0055","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1146\/annurev.immunol.15.1.235","article-title":"Neutralizing antiviral B cell responses","volume":"15","author":"Bachmann","year":"1997","journal-title":"Annu. Rev. Immunol."},{"issue":"4\u20135","key":"10.1016\/j.ijbiomac.2023.123979_bb0060","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.addr.2009.11.011","article-title":"Application of nanotechnologies for improved immune response against infectious diseases in the developing world","volume":"62","author":"Look","year":"2010","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0065","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4161\/hv.22218","article-title":"Plant-derived virus-like particles as vaccines","volume":"9","author":"Chen","year":"2013","journal-title":"Hum. Vacc. Immunother."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.123979_bb0070","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1038\/s41591-021-01370-1","article-title":"Phase 1 randomized trial of a plant-derived virus-like particle vaccine for COVID-19","volume":"27","author":"Ward","year":"2021","journal-title":"Nat. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.123979_bb0075","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/14728222.2010.501333","article-title":"Targeting the TLR9-MyD88 pathway in the regulation of adaptive immune responses","volume":"14","author":"Huang","year":"2010","journal-title":"Expert Opin. Ther. Targets"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0080","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/all.15091","article-title":"Development and preclinical evaluation of virus-like particle vaccine against COVID-19 infection","volume":"77","author":"Yilmaz","year":"2021","journal-title":"Allergy"},{"issue":"35","key":"10.1016\/j.ijbiomac.2023.123979_bb0085","doi-asserted-by":"crossref","first-page":"4988","DOI":"10.1016\/j.vaccine.2021.07.034","article-title":"An enveloped virus-like particle vaccine expressing a stabilized prefusion form of the SARS-CoV-2 spike protein elicits highly potent immunity","volume":"39","author":"Fluckiger","year":"2021","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.123979_bb0090","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/14760584.3.2.119","article-title":"Recombivax-HB: perspectives past, present and future","volume":"3","author":"Venters","year":"2004","journal-title":"Expert Rev. Vacc."},{"issue":"Suppl 2","key":"10.1016\/j.ijbiomac.2023.123979_bb0095","first-page":"169","article-title":"Summary of clinical findings on engerix-B, a genetically engineered yeast derived hepatitis B vaccine","volume":"63","author":"Andr\u00e9","year":"1987","journal-title":"Postgrad. Med. J."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0100","doi-asserted-by":"crossref","first-page":"90","DOI":"10.4161\/hv.6.1.9677","article-title":"From the circumsporozoite protein to the RTS, S\/AS candidate vaccine","volume":"6","author":"Cohen","year":"2010","journal-title":"Hum. Vacc."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0105","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1038\/s41467-020-20251-8","article-title":"Capsid-like particles decorated with the SARS-CoV-2 receptor-binding domain elicit strong virus neutralization activity","volume":"12","author":"Fougeroux","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ijbiomac.2023.123979_bb0110","doi-asserted-by":"crossref","first-page":"862","DOI":"10.3389\/fbioe.2020.00862","article-title":"Construction of SARS-CoV-2 virus-like particles by mammalian expression system","volume":"8","author":"Xu","year":"2020","journal-title":"Front. Bioeng. Biotechnol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0115","doi-asserted-by":"crossref","first-page":"21877","DOI":"10.1038\/s41598-020-78656-w","article-title":"Minimal system for assembly of SARS-CoV-2 virus like particles","volume":"10","author":"Swann","year":"2020","journal-title":"Sci. Rep."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.123979_bb0120","doi-asserted-by":"crossref","first-page":"554","DOI":"10.3390\/vaccines9060554","article-title":"Production of SARS-CoV-2 virus-like particles in insect cells","volume":"9","author":"Mi","year":"2021","journal-title":"Vaccines"},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.123979_bb0125","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/s41422-020-00392-7","article-title":"A COVID-19 mRNA vaccine encoding SARS-CoV-2 virus-like particles induces a strong antiviral-like immune response in mice","volume":"30","author":"Lu","year":"2020","journal-title":"Cell Res."},{"issue":"8","key":"10.1016\/j.ijbiomac.2023.123979_bb0130","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3390\/vaccines9080920","article-title":"Influenza virus-like particle (VLP) vaccines expressing the SARS-CoV-2 S glycoprotein, S1, or S2 domains","volume":"9","author":"Chu","year":"2021","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.123979_bb0135","doi-asserted-by":"crossref","first-page":"4673","DOI":"10.1128\/JVI.02306-09","article-title":"The lack of an inherent membrane targeting signal is responsible for the failure of the matrix (M1) protein of influenza a virus to bud into virus-like particles","volume":"84","author":"Wang","year":"2010","journal-title":"J. Virol."},{"issue":"38","key":"10.1016\/j.ijbiomac.2023.123979_bb0140","doi-asserted-by":"crossref","first-page":"6606","DOI":"10.1016\/j.vaccine.2011.06.111","article-title":"Chimeric severe acute respiratory syndrome coronavirus (SARS-CoV) S glycoprotein and influenza matrix 1 efficiently form virus-like particles (VLPs) that protect mice against challenge with SARS-CoV","volume":"29","author":"Liu","year":"2011","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.123979_bb0145","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s12250-018-0064-8","article-title":"Significant spike-specific IgG and neutralizing antibodies in mice induced by a novel chimeric virus-like particle vaccine candidate for Middle East respiratory syndrome coronavirus","volume":"33","author":"Lan","year":"2018","journal-title":"Virol. Sin."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.123979_bb0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/vaccines9020073","article-title":"Newcastle disease virus-like particles displaying prefusion-stabilized SARS-CoV-2 spikes elicit potent neutralizing responses","volume":"9","author":"Yang","year":"2021","journal-title":"Vaccines"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.123979_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9040403","article-title":"AP205 VLPs based on dimerized capsid proteins accommodate RBM domain of SARS-CoV-2 and serve as an attractive vaccine candidate","volume":"9","author":"Liu","year":"2021","journal-title":"Vaccines"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0160","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/s42003-021-02128-8","article-title":"Multivalent nanoparticle-based vaccines protect hamsters against SARS-CoV-2 after a single immunization","volume":"4","author":"Chiba","year":"2021","journal-title":"Commun. Biol."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.123979_bb0165","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10875-005-2820-4","article-title":"Immunogenic properties of a chimeric plant virus expressing a hepatitis C virus (HCV)-derived epitope: new prospects for an HCV vaccine","volume":"25","author":"Piazzolla","year":"2005","journal-title":"J. Clin. Immunology"},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.123979_bb0170","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/vaccines5020010","article-title":"Virus-like particle (VLP) plus microcrystalline tyrosine (MCT) adjuvants enhance vaccine efficacy improving T and B cell immunogenicity and protection against plasmodium berghei\/vivax","volume":"5","author":"Cabral-Miranda","year":"2017","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2023.123979_bb0175","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41541-017-0030-8","article-title":"Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer's and cat allergy","volume":"2","author":"Zeltins","year":"2017","journal-title":"NPJ Vaccines"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0180","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1111\/all.15080","article-title":"A scalable and highly immunogenic virus-like particle-based vaccine against SARS-CoV-2","volume":"77","author":"Mohsen","year":"2021","journal-title":"Allergy"},{"issue":"4","key":"10.1016\/j.ijbiomac.2023.123979_bb0185","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines9040395","article-title":"Development of a vaccine against SARS-CoV-2 based on the receptor-binding domain displayed on virus-like particles","volume":"9","author":"Zha","year":"2021","journal-title":"Vaccines"},{"issue":"10","key":"10.1016\/j.ijbiomac.2023.123979_bb0190","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1039\/C8CS00154E","article-title":"Tailoring lumazine synthase assemblies for bionanotechnology","volume":"47","author":"Azuma","year":"2018","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijbiomac.2023.123979_bb0195","article-title":"Second career of a biosynthetic enzyme: lumazine synthase as a virus-like nanoparticle in vaccine development","volume":"27","author":"Ladenstein","year":"2020","journal-title":"Biotechnol. Rep. (Amst)"},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.123979_bb0200","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009897","article-title":"Novel virus-like nanoparticle vaccine effectively protects animal model from SARS-CoV-2 infection","volume":"17","author":"Geng","year":"2021","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0205","doi-asserted-by":"crossref","first-page":"18149","DOI":"10.1038\/s41598-020-74949-2","article-title":"A platform incorporating trimeric antigens into self-assembling nanoparticles reveals SARS-CoV-2-spike nanoparticles to elicit substantially higher neutralizing responses than spike alone","volume":"10","author":"Zhang","year":"2020","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.123979_bb0210","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1021\/acs.bioconjchem.1c00208","article-title":"Self-assembling nanoparticle vaccines displaying the receptor binding domain of SARS-CoV-2 elicit robust protective immune responses in rhesus monkeys","volume":"32","author":"Li","year":"2021","journal-title":"Bioconjug. Chem."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.123979_bb0215","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00230-21","article-title":"Development of spike receptor-binding domain nanoparticles as a vaccine candidate against SARS-CoV-2 infection in ferrets","volume":"12","author":"Kim","year":"2021","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0220","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1021\/acscentsci.0c01405","article-title":"A single immunization with spike-functionalized ferritin vaccines elicits neutralizing antibody responses against SARS-CoV-2 in mice","volume":"7","author":"Powell","year":"2021","journal-title":"ACS Cent. Sci."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0225","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/s41392-021-00750-w","article-title":"The self-assembled nanoparticle-based trimeric RBD mRNA vaccine elicits robust and durable protective immunity against SARS-CoV-2 in mice","volume":"6","author":"Sun","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.123979_bb0230","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/s41423-021-00643-6","article-title":"Ferritin nanoparticle-based SARS-CoV-2 RBD vaccine induces a persistent antibody response and long-term memory in mice","volume":"18","author":"Wang","year":"2021","journal-title":"Cellular & molecular immunology"},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.123979_bb0235","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/j.immuni.2020.11.015","article-title":"Nanoparticle vaccines based on the receptor binding domain (RBD) and heptad repeat (HR) of SARS-CoV-2 elicit robust protective immune responses","volume":"53","author":"Ma","year":"2020","journal-title":"Immunity"},{"issue":"18","key":"10.1016\/j.ijbiomac.2023.123979_bb0240","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1002\/1873-3468.14171","article-title":"Single-dose immunisation with a multimerised SARS-CoV-2 receptor binding domain (RBD) induces an enhanced and protective response in mice","volume":"595","author":"Salzer","year":"2021","journal-title":"FEBS Lett."},{"issue":"7610","key":"10.1016\/j.ijbiomac.2023.123979_bb0245","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/nature18010","article-title":"Design of a hyperstable 60-subunit protein dodecahedron","volume":"535","author":"Hsia","year":"2016","journal-title":"Nature"},{"issue":"9","key":"10.1016\/j.ijbiomac.2023.123979_bb0250","doi-asserted-by":"crossref","first-page":"8855","DOI":"10.1021\/acsnano.8b02805","article-title":"Engineering a rugged nanoscaffold to enhance plug-and-display vaccination","volume":"12","author":"Bruun","year":"2018","journal-title":"ACS Nano"},{"issue":"11","key":"10.1016\/j.ijbiomac.2023.123979_bb0255","doi-asserted-by":"crossref","first-page":"eaau6769","DOI":"10.1126\/sciadv.aau6769","article-title":"HIV-1 vaccine design through minimizing envelope metastability","volume":"4","author":"He","year":"2018","journal-title":"Sci. Adv."},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0260","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41467-020-20654-7","article-title":"A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses","volume":"12","author":"Tan","year":"2021","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.123979_bb0265","doi-asserted-by":"crossref","DOI":"10.1002\/btm2.10253","article-title":"Potent neutralization of SARS-CoV-2 including variants of concern by vaccines presenting the receptor-binding domain multivalently from nanoscaffolds","volume":"6","author":"Halfmann","year":"2021","journal-title":"Bioeng. Transl.Med."},{"issue":"2","key":"10.1016\/j.ijbiomac.2023.123979_bb0270","doi-asserted-by":"crossref","first-page":"2738","DOI":"10.1021\/acsnano.0c08379","article-title":"Rapid development of SARS-CoV-2 spike protein receptor-binding domain self-assembled nanoparticle vaccine candidates","volume":"15","author":"Kang","year":"2021","journal-title":"ACS Nano"},{"issue":"12","key":"10.1016\/j.ijbiomac.2023.123979_bb0275","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abf1591","article-title":"Single-component, self-assembling, protein nanoparticles presenting the receptor binding domain and stabilized spike as SARS-CoV-2 vaccine candidates","volume":"7","author":"He","year":"2021","journal-title":"Sci. Adv."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.123979_bb0280","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/j.cell.2021.01.035","article-title":"Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection","volume":"184","author":"Brouwer","year":"2021","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.123979_bb0285","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1016\/j.cell.2020.10.043","article-title":"Elicitation of potent neutralizing antibody responses by designed protein nanoparticle vaccines for SARS-CoV-2","volume":"183","author":"Walls","year":"2020","journal-title":"Cell"},{"issue":"12","key":"10.1016\/j.ijbiomac.2023.123979_bb0290","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/nm.3985","article-title":"A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence","volume":"21","author":"Menachery","year":"2015","journal-title":"Nat. Med."},{"issue":"11","key":"10.1016\/j.ijbiomac.2023.123979_bb0295","doi-asserted-by":"crossref","first-page":"3048","DOI":"10.1073\/pnas.1517719113","article-title":"SARS-like WIV1-CoV poised for human emergence","volume":"113","author":"Menachery","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"6530","key":"10.1016\/j.ijbiomac.2023.123979_bb0300","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.abf6840","article-title":"Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice","volume":"371","author":"Cohen","year":"2021","journal-title":"Science"},{"issue":"21","key":"10.1016\/j.ijbiomac.2023.123979_bb0305","doi-asserted-by":"crossref","first-page":"5432","DOI":"10.1016\/j.cell.2021.09.015","article-title":"Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines","volume":"184","author":"Walls","year":"2021","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ijbiomac.2023.123979_bb0310","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1038\/s41467-022-30222-w","article-title":"Quadrivalent mosaic HexaPro-bearing nanoparticle vaccine protects against infection of SARS-CoV-2 variants","volume":"13","author":"Kang","year":"2022","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.123979_bb0315","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1006\/jmbi.1993.1616","article-title":"The refined structure of bacteriophage MS2 at 2.8 a resolution","volume":"234","author":"Golmohammadi","year":"1993","journal-title":"J. Mol. Biol."},{"issue":"21","key":"10.1016\/j.ijbiomac.2023.123979_bb0320","doi-asserted-by":"crossref","first-page":"4267","DOI":"10.1016\/j.jmb.2016.08.025","article-title":"Structure of AP205 coat protein reveals circular permutation in ssRNA bacteriophages","volume":"428","author":"Shishovs","year":"2016","journal-title":"J. Mol. Biol."},{"issue":"16","key":"10.1016\/j.ijbiomac.2023.123979_bb0325","doi-asserted-by":"crossref","first-page":"7578","DOI":"10.1128\/JVI.74.16.7578-7586.2000","article-title":"The structure of cucumber mosaic virus and comparison to cowpea chlorotic mottle virus","volume":"74","author":"Smith","year":"2000","journal-title":"J. Virol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2023.123979_bb0330","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s007750050310","article-title":"Crystal structure of bullfrog M ferritin at 2.8 a resolution: analysis of subunit interactions and the binuclear metal center","volume":"4","author":"Ha","year":"1999","journal-title":"J. Biol. Inorg. Chem."},{"issue":"5","key":"10.1016\/j.ijbiomac.2023.123979_bb0335","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1006\/jmbi.2000.4435","article-title":"X-ray structure analysis and crystallographic refinement of lumazine synthase from the hyperthermophile aquifex aeolicus at 1.6 a resolution: determinants of thermostability revealed from structural comparisons","volume":"306","author":"Zhang","year":"2001","journal-title":"J. Mol. Biol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2023.123979_bb0340","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus","volume":"176","author":"Marcandalli","year":"2019","journal-title":"Cell"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813023008735?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813023008735?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T04:52:08Z","timestamp":1786769528000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813023008735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":68,"alternative-id":["S0141813023008735"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.123979","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2023.123979","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"123979"}}